Plerixafor (Mozobil)
Jump to navigation
Jump to search
General information
Class/mechanism: Mobilizes hematopoetic stem cells by inhibiting the CXCR4 chemokine receptor and blocking its cognate ligand, stromal cell-derived factor-1α (SDF-1α). One function of CXCR4 is to anchor stem cells to the marrow matrix via SDF-1α or other adhesion molecules.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in EMA indication
- 2009-07-30: Initial authorization
History of changes in PMDA indications
- 2016-12-19: Initial approval for the enhancement of mobilization of hematopoietic stem cells to the peripheral blood for autologous peripheral blood stem cell transplantation.
Also known as
- Code name: AMD-3100
- Brand name: Mozobil